Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Strategies to Overcome Resistance in Driver-Mutant NSCLC
NCT02949843Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Mar 2017
- Primary completion
- Jan 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Wake Forest University Health Sciences. Started Mar 2017; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02949843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949843.